Niagen Bioscience, Inc. (NAGE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Niagen Bioscience, Inc. (NAGE) has a cash flow conversion efficiency ratio of 0.052x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.69 Million) by net assets ($70.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Niagen Bioscience, Inc. - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Niagen Bioscience, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Niagen Bioscience, Inc. (NAGE) financial obligations for a breakdown of total debt and financial obligations.
Niagen Bioscience, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Niagen Bioscience, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alltek Technology Corp
TW:3209
|
-0.227x |
|
Eik fasteignafélag hf
IC:EIK
|
0.017x |
|
Shanghai DOBE Cultural & Creative Industry Development (Group) Co. LTD.
SHE:300947
|
N/A |
|
Hanyang ENG Co. Ltd
KQ:045100
|
0.043x |
|
Calfrac Well Services Ltd.
TO:CFW
|
0.069x |
|
Ananti Inc
KQ:025980
|
0.033x |
|
Altshuler Shaham Financial LTD
TA:ALTF
|
-0.209x |
|
Beijing Sanfo Outdoor Products Co Ltd
SHE:002780
|
-0.032x |
Annual Cash Flow Conversion Efficiency for Niagen Bioscience, Inc. (2007–2024)
The table below shows the annual cash flow conversion efficiency of Niagen Bioscience, Inc. from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see NAGE company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $46.09 Million | $12.11 Million | 0.263x | +5.04% |
| 2023-12-31 | $28.46 Million | $7.12 Million | 0.250x | +147.50% |
| 2022-12-31 | $28.67 Million | $-15.10 Million | -0.527x | +30.86% |
| 2021-12-31 | $31.73 Million | $-24.16 Million | -0.762x | -18.00% |
| 2020-12-31 | $16.42 Million | $-10.60 Million | -0.645x | +35.44% |
| 2019-12-31 | $20.45 Million | $-20.44 Million | -1.000x | -29.95% |
| 2018-12-31 | $27.18 Million | $-20.91 Million | -0.769x | -322.42% |
| 2017-12-31 | $53.83 Million | $-9.80 Million | -0.182x | +38.14% |
| 2016-12-31 | $9.97 Million | $-2.94 Million | -0.294x | +26.44% |
| 2015-12-31 | $5.27 Million | $-2.11 Million | -0.400x | +37.98% |
| 2014-12-31 | $4.00 Million | $-2.58 Million | -0.645x | +6.39% |
| 2013-12-31 | $5.67 Million | $-3.91 Million | -0.689x | +72.79% |
| 2012-12-31 | $3.99 Million | $-10.12 Million | -2.534x | -58.35% |
| 2011-12-31 | $2.56 Million | $-4.10 Million | -1.600x | -196.80% |
| 2010-12-31 | $4.94 Million | $-2.66 Million | -0.539x | -42.56% |
| 2009-12-31 | $1.05 Million | $-396.17K | -0.378x | +65.57% |
| 2008-12-31 | $1.75 Million | $-1.92 Million | -1.098x | +99.49% |
| 2007-12-31 | $180.00 | $-38.48K | -213.794x | -- |
About Niagen Bioscience, Inc.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+)… Read more